Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gen...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/11/2752 |
| _version_ | 1797493824723877888 |
|---|---|
| author | Aida Vitkevičienė Giedrė Skliutė Andrius Žučenka Veronika Borutinskaitė Rūta Navakauskienė |
| author_facet | Aida Vitkevičienė Giedrė Skliutė Andrius Žučenka Veronika Borutinskaitė Rūta Navakauskienė |
| author_sort | Aida Vitkevičienė |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gene level differences between refractory and responsive AML patient groups at diagnosis stage and after clinical treatment using RT-qPCR. We demonstrated that oncogenic <i>MYC</i> and <i>WT1</i> and metabolic <i>IDH1</i> gene expression was significantly higher and cell cycle inhibitor <i>CDKN1A (p21)</i> gene expression was significantly lower in refractory patients’ bone marrow cells compared to treatment responsive patients both at diagnosis and after clinical treatment. Moreover, we determined that, compared to clinical treatment responsive patients, refractory patients possess a significantly higher gene expression of histone deacetylase 2 (<i>HDAC2</i>) and epigenetic DNA modulator <i>TET1</i> and a significantly lower gene expression of lysine acetyltransferase 6A (<i>KAT6A</i>) and nucleosome remodeling and deacetylase (NuRD) complex component <i>GATAD2A</i>. We suggest that <i>MYC</i>, <i>WT1</i>, <i>IDH1</i>, <i>CDKN1A</i>, <i>HDAC2</i>, <i>TET1</i>, <i>KAT6A</i> and <i>GATAD2A</i> gene expression changes might characterize refractory AML. Thus, they might be useful for AML prognosis. Additionally, we suggest that epigenetic modulation might be beneficial in combination with standard treatment. |
| first_indexed | 2024-03-10T01:25:30Z |
| format | Article |
| id | doaj.art-18b73d850d544fc98b4b5d1f2be4ae8b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:25:30Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-18b73d850d544fc98b4b5d1f2be4ae8b2023-11-23T13:50:33ZengMDPI AGCancers2072-66942022-06-011411275210.3390/cancers14112752Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid LeukemiaAida Vitkevičienė0Giedrė Skliutė1Andrius Žučenka2Veronika Borutinskaitė3Rūta Navakauskienė4Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-01257 Vilnius, LithuaniaDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-01257 Vilnius, LithuaniaHematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu str. 2, LT-08661 Vilnius, LithuaniaDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-01257 Vilnius, LithuaniaDepartment of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-01257 Vilnius, LithuaniaAcute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gene level differences between refractory and responsive AML patient groups at diagnosis stage and after clinical treatment using RT-qPCR. We demonstrated that oncogenic <i>MYC</i> and <i>WT1</i> and metabolic <i>IDH1</i> gene expression was significantly higher and cell cycle inhibitor <i>CDKN1A (p21)</i> gene expression was significantly lower in refractory patients’ bone marrow cells compared to treatment responsive patients both at diagnosis and after clinical treatment. Moreover, we determined that, compared to clinical treatment responsive patients, refractory patients possess a significantly higher gene expression of histone deacetylase 2 (<i>HDAC2</i>) and epigenetic DNA modulator <i>TET1</i> and a significantly lower gene expression of lysine acetyltransferase 6A (<i>KAT6A</i>) and nucleosome remodeling and deacetylase (NuRD) complex component <i>GATAD2A</i>. We suggest that <i>MYC</i>, <i>WT1</i>, <i>IDH1</i>, <i>CDKN1A</i>, <i>HDAC2</i>, <i>TET1</i>, <i>KAT6A</i> and <i>GATAD2A</i> gene expression changes might characterize refractory AML. Thus, they might be useful for AML prognosis. Additionally, we suggest that epigenetic modulation might be beneficial in combination with standard treatment.https://www.mdpi.com/2072-6694/14/11/2752acute myeloid leukemia (AML)prognostic markersepigenetic regulation |
| spellingShingle | Aida Vitkevičienė Giedrė Skliutė Andrius Žučenka Veronika Borutinskaitė Rūta Navakauskienė Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia Cancers acute myeloid leukemia (AML) prognostic markers epigenetic regulation |
| title | Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia |
| title_full | Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia |
| title_fullStr | Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia |
| title_full_unstemmed | Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia |
| title_short | Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia |
| title_sort | potential prognostic markers for relapsed refractory vs responsive acute myeloid leukemia |
| topic | acute myeloid leukemia (AML) prognostic markers epigenetic regulation |
| url | https://www.mdpi.com/2072-6694/14/11/2752 |
| work_keys_str_mv | AT aidavitkeviciene potentialprognosticmarkersforrelapsedrefractoryvsresponsiveacutemyeloidleukemia AT giedreskliute potentialprognosticmarkersforrelapsedrefractoryvsresponsiveacutemyeloidleukemia AT andriuszucenka potentialprognosticmarkersforrelapsedrefractoryvsresponsiveacutemyeloidleukemia AT veronikaborutinskaite potentialprognosticmarkersforrelapsedrefractoryvsresponsiveacutemyeloidleukemia AT rutanavakauskiene potentialprognosticmarkersforrelapsedrefractoryvsresponsiveacutemyeloidleukemia |